2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative

…, DE Furst, A Gabrielli, MD Mayes… - Arthritis & …, 2013 - Wiley Online Library
Objective The 1980 American College of Rheumatology (ACR) classification criteria for
systemic sclerosis (SSc) lack sensitivity for early SSc and limited cutaneous SSc. The present …

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I

…, MH Liang, HM Kremers, MD Mayes… - Arthritis & …, 2008 - Wiley Online Library
Objective. To provide a single source for the best available estimates of the US prevalence of
and number of individuals affected by arthritis overall, rheumatoid arthritis, juvenile arthritis, …

Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population

MD Mayes, JV Lacey Jr… - … : Official Journal of …, 2003 - Wiley Online Library
Objective To estimate the prevalence, incidence, survival, and disease characteristics of
systemic sclerosis (SSc) in the Detroit tricounty area. Methods A census of SSc cases for the …

[HTML][HTML] Nintedanib for systemic sclerosis–associated interstitial lung disease

…, A Azuma, A Fischer, MD Mayes… - … England Journal of …, 2019 - Mass Medical Soc
Background Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis
and a leading cause of systemic sclerosis–related death. Nintedanib, a tyrosine kinase …

2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative

…, O Distler, Y Allanore, DE Furst, A Gabrielli, MD Mayes… - 2013 - deepblue.lib.umich.edu
Objective. The 1980 American College of Rheuma-tology (ACR) classification criteria for
systemic sclerosis (SSc) lack sensitivity for early SSc and limited cutaneous SSc. The present …

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

…, CP Denton, DE Furst, MD Mayes… - Annals of the …, 2011 - ard.bmj.com
Objectives Ischaemic digital ulcers (DUs) are common in patients with systemic sclerosis (SSc)
and are a cause of disease-related morbidity. In an earlier trial, treatment with bosentan, …

[HTML][HTML] Myeloablative autologous stem-cell transplantation for severe scleroderma

…, A Pinckney, B Welch, MD Mayes… - … England Journal of …, 2018 - Mass Medical Soc
Background Despite current therapies, diffuse cutaneous systemic sclerosis (scleroderma)
often has a devastating outcome. We compared myeloablative CD34+ selected autologous …

Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo‐controlled phase I/II trial of CAT …

…, F Hoogen, A Herrick, MD Mayes, D Veale… - Arthritis & …, 2007 - Wiley Online Library
Objective To evaluate CAT‐192, a recombinant human antibody that neutralizes transforming
growth factor β1 (TGFβ1), in the treatment of early‐stage diffuse cutaneous systemic …

Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon

…, RW Martin, JJ Anderson, MD Mayes… - Arthritis & …, 2002 - Wiley Online Library
Objective To document disease activity and functional status in patients with scleroderma (systemic
sclerosis [SSc]) and Raynaud's phenomenon (RP) and to determine the sensitivity to …

Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus

…, BPC Koeleman, FC Arnett, J Martin, MD Mayes - Nature …, 2010 - nature.com
Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of the skin and
internal organs that leads to profound disability and premature death. To identify new SSc …